NASDAQ: LIMN
Liminatus Pharma Inc Stock Ownership - Who owns Liminatus Pharma?

Insider buying vs selling

Have Liminatus Pharma Inc insiders been buying or selling?

No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when LIMN insiders and whales buy or sell their stock.

LIMN Shareholders

What type of owners hold Liminatus Pharma Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Iris Acquisition Holdings LLC25.49%6,900,000$9.59MInsider
Valetudo Therapeutics LLC22.80%6,169,406$8.58MInsider
Chris Kim22.80%6,169,406$8.58MInsider
Kh Feelux Co Ltd14.78%4,000,000$5.56MInsider
Vanguard Group Inc0.27%73,424$102.06kInstitution
Geode Capital Management LLC0.24%63,841$88.74kInstitution
Ubs Group Ag0.12%31,486$43.77kInstitution
State Street Corp0.07%19,000$26.41kInstitution
Blackrock Inc0.05%13,255$18.42kInstitution
Royal Bank Of Canada0.01%2,886$4.01kInstitution

1 of 2

LIMN vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
LIMN0.76%85.86%
RADX0.01%0.00%
GBIO58.82%41.18%Net BuyingNet Selling
JSPR20.42%79.58%Net BuyingNet Buying
HYPD0.72%99.28%

Liminatus Pharma Stock Ownership FAQ

Who owns Liminatus Pharma?

Liminatus Pharma (NASDAQ: LIMN) is owned by 0.76% institutional shareholders, 85.86% Liminatus Pharma insiders, and 13.38% retail investors. Iris Acquisition Holdings LLC is the largest individual Liminatus Pharma shareholder, owning 6.90M shares representing 25.49% of the company. Iris Acquisition Holdings LLC's Liminatus Pharma shares are currently valued at $9.59M.

If you're new to stock investing, here's how to buy Liminatus Pharma stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.